Business
Peer-reviewed publication on Moditope® platform
Peer-reviewed publication on Moditope® platform.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0030E Scancell Holdings Plc 13 July 2016 \n\nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nPeer-reviewed publication highlights advantages of Moditope® technology platform\n \n Potential to develop completely new class of immuno-oncology therapeutics\n \n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of an invited review in the scientific journal Autophagy entitled: \"Autophagy, citrullination and cancer\", which describes Scancell's pre-clinical data that supports the innovation and potential of the Company's Moditope® platform1. \n \nThe review, whose lead author is Professor Lindy Durrant, Scancell's Chief Scientific Officer, discusses the concept that citrullinated peptides produced during autophagy offer attractive vaccine targets for cancer therapy. Scancell's Moditope® platform utilises this mechanism to stimulate the production of highly active CD4+ T cells that overcome self-tolerance and destroy tumour cells. \n \nThe data described in the review, and published in the peer-reviewed journal Cancer Research2, showed that a single immunization with Moditope® peptides, up to 14 days after tumour implant, resulted in long-term survival in up to 90% of mice, with no associated toxicity. \n \nProfessor Lindy Durrant, Chief Scientific Officer of Scancell commented:\n \n\"The interplay between autophagy, citrullination and cancer support the rationale behind our Moditope® platform technology. Moditope® has a unique mechanism of action that overcomes the immune suppression induced by tumour cells, allowing T cells to seek out and kill tumours that would otherwise be hidden from the immune system. We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible.\" \n \nThe first clinical trials of Modi-1, the lead candidate from the Moditiope® platform, are expected to target patients with triple negative breast cancer, ovarian cancer and osteosarcoma.\n \nThe full abstract of the review can be found below. \n \nAbstract\n \nAutophagy, citrullination and cancer\n \nA cell needs to maintain a ...